All In Biotech

NDA 208171 · Pharmacosmos

Monoferric

Ferric Derisomaltose · Intravenous

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Jan 16, 2020

Approved uses

2

Original approval plus efficacy supplements

Registered trials

39

16 Phase 3, 18 recruiting

FAERS reports

1,366

726 serious, 51 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 29, 2026.

Monoferric is indicated for the treatment of iron deficiency anemia (IDA) in adult patients: who have intolerance to oral iron or have had unsatisfactory response to oral iron, or who have non-hemodialysis-dependent chronic kidney disease (NDD-CKD) MONOFERRIC is an iron replacement product indicated for the treatment of iron deficiency anemia in adult patients: who have intolerance to oral iron or have had unsatisfactory response to oral iron. ( 1 ) who have non-hemodialysis-dependent chronic kidney disease. ( 1 )

Mechanism: Ferric derisomaltose is a complex of iron (III) hydroxide and derisomaltose, an iron carbohydrate oligosaccharide that releases iron. Iron binds to transferrin for transport to erythroid precursor cells to be incorporated into hemoglobin.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 23, 2026 Supplement 6 · Efficacy LetterLabel
  • Jan 16, 2020 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
3 products under this application
  • MONOFERRIC · FERRIC DERISOMALTOSE 1GM/10ML (100MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • MONOFERRIC · FERRIC DERISOMALTOSE 100MG/ML (100MG/ML) · SOLUTION, INTRAVENOUS · Discontinued
  • MONOFERRIC · FERRIC DERISOMALTOSE 500MG/5ML (100MG/ML) · SOLUTION, INTRAVENOUS · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Ferric Derisomaltose" as an intervention, any sponsor and status, largest first.

All 39 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea288
  • nausea162
  • flushing157
  • chest discomfort150
  • back pain127
  • infusion related reaction104
  • dizziness100
  • vomiting92
  • pruritus90
  • chest pain87
  • abdominal pain74
  • hypersensitivity69

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20161
20206
2021153
2022189
2023269
2024272
2025282
2026194

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Monoferric (Ferric DerIsomaltose) · HCPCS J1437

2024 spending

$108M

Beneficiaries

41,968

54,664 claims

Per beneficiary

$2,572

2024 ASP limit $20.12 per unit

View as table
YearSpending
2020$287,847
2021$13,124,539
2022$32,393,441
2023$69,618,170
2024$107,960,139

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 55 on PubMed

Sponsor: Pharmacosmos

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.